Placeholder Banner

Biotech Leader Rachel King Urges President Trump to Reject Foreign Price Controls, Ensure U.S. Continues to Lead in Innovation

January 31, 2020
Media Contact
Author-Profile-Andrew-Segerman

Rachel King is co-founder and CEO of GlycoMimetics, a biotech company based in Rockville, Maryland that is working hard to develop new treatments for patients with various diseases of the blood. In a new video, Mrs. King explains why President Trump’s plan to impose foreign price controls on certain medicines would “directly inhibit” the ability of small biotech startups to attract the investments necessary to bring new cures and treatments to patients. Mrs. King adds the international reference pricing is “not the right way” to lower prescription drugs costs and calls on the president to ensure America continues to lead the world in biomedical innovation. 

“Investors can put their money wherever they want to. Investors can put their money into apps, they can put them into cell phones, they can put them into IT … or they can put their money into developing new drugs.
 
“If we change the incentives and if we decrease the incentives for investing in new drugs, the money will flow out of the biotechnology industry and the United States risks losing its lead position in biotechnology.”

To learn more about the flaws of importing foreign price controls, visit bio.org/save-cures.
 

Discover More
The Biotechnology Innovation Organization (BIO) this week hosted a productive virtual summit intended to foster collaboration among key government agencies and biopharmaceutical innovators with one goal: eradicating Covid-19. The two-day virtual…
Companies are Coming Together to Achieve Shared Goal of Eradicating the Virus  Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Innovation Organization (BIO) underscored the industry’s commitment…
BIO-Led Summit to Build Collaboration Between Biopharma Industry, Government Leaders & Scientific Experts  Responding to the rapidly evolving COVID-19 public health crisis, the Biotechnology Innovation Organization (BIO) is taking the…